GVP Module VIII: PASS Results, Reporting and Regulatory Follow-up

Introduction

A post-authorisation safety study is undertaken because a pharmacovigilance question cannot be adequately answered by the information already available. Once the study produces evidence, the organisation has to determine what that evidence means in relation to the original question, how reliable the answer is, and whether the new evidence changes anything in the wider pharmacovigilance system.

This makes results reporting more than a documentation exercise. The protocol establishes the question and method; study conduct generates the evidence; analysis turns data into results; interpretation determines what those results can reasonably support; and follow-up determines whether the evidence requires further pharmacovigilance or regulatory action.

For an imposed non-interventional PASS, the final study report also enters a formal EU regulatory procedure. For a voluntary PASS, the formal route can differ, although the MAH still needs to assess the pharmacovigilance significance of the findings. EMA currently lists GVP Module VIII Revision 3 as the applicable module and provides separate procedural guidance for imposed non-interventional PASS. citeturn1view1turn0search1

The subject is therefore best understood as one connected process:

Safety question
      ↓
Protocol and study conduct
      ↓
Data and analysis
      ↓
Interpretation
      ↓
Interim or final reporting
      ↓
Pharmacovigilance / regulatory assessment
      ↓
Action and follow-up

Each stage answers a different question. Keeping them distinct makes both the science and the governance easier to evaluate.

1. The Result Must Be Interpreted Against the Original Question

The starting point for interpreting a PASS result is the protocol. The organisation should be able to identify the primary objective, study population, exposure definition, outcome definition and principal analysis before deciding what the result means.

This is important because a study can generate findings outside its primary objective. Such findings may be important and may require further assessment, but they should not silently replace the question the study was designed to answer.

A useful review therefore asks three sequential questions:

1. What did the protocol intend to establish?
2. What did the study actually establish?
3. What remains uncertain?

The answers provide the foundation for the final scientific conclusion.

2. From Data to a Defensible Scientific Conclusion

A numerical result is not, by itself, a pharmacovigilance conclusion. The result has to be interpreted in the context of the study design and its limitations.

For an epidemiological PASS, interpretation may need to consider effect size and precision, exposure measurement, outcome ascertainment, confounding, selection, missing data and other sources of bias. For a study evaluating risk-minimisation effectiveness, the relevant question may instead concern whether the intervention achieved its predefined objective and whether the observed effect is sufficient to support a conclusion about effectiveness.

The central principle is that the conclusion should not claim more than the design and evidence can support. A statistically significant association does not automatically establish causality, while a non-significant result does not establish that a risk is absent.

The scientific conclusion should therefore distinguish evidence, interpretation and uncertainty rather than compressing all three into a single statement.

3. The Analytical Dataset and the Meaning of Finality

The distinction between interim and final results becomes particularly important for an imposed non-interventional PASS because the regulatory reporting clock is linked to the end of data collection.

EMA's current procedural guidance explains that the end of data collection is tied to the availability of the analytical dataset needed to perform the statistical analyses leading to the primary study results. Only reports considered final by the MAH should be submitted as final study reports. Where the analytical dataset is incomplete or data are still being collected, EMA advises contacting the Agency before submitting the report as final. citeturn1view1

This prevents an important category error: project completion is not necessarily the same as scientific finality.

The organisation should therefore define and document the milestone using controlled study records rather than relying on an informal statement that data collection has finished.

4. The Final Study Report Connects Method to Conclusion

The final study report should allow an informed reader to understand what was planned, what was done, what was analysed and how the conclusion was reached.

For non-interventional PASS, EU requirements and EMA guidance establish the format and content of final study reports. EMA also provides a dedicated template for assessment of imposed PASS final study reports. citeturn1view1

The report should preserve a traceable chain:

Protocol objective
      ↓
Population and data source
      ↓
Study conduct
      ↓
Analytical dataset
      ↓
Analysis
      ↓
Results
      ↓
Limitations
      ↓
Interpretation
      ↓
Conclusion

This is more useful than treating the report as a collection of tables followed by a conclusion. The conclusion should be demonstrably derived from the evidence presented in the report.

5. Protocol Deviations Must Be Reflected in the Interpretation

The final report should make material departures from the planned methodology visible.

A deviation is not automatically evidence that the study failed. The relevant question is whether it affected the validity or interpretation of the results.

The assessment should consider, as applicable:

• study population;
• exposure classification;
• outcome ascertainment;
• data completeness;
• statistical analysis;
• interpretation;
• and the reliability of the final conclusion.

Where an important deviation has no material impact, that conclusion should still be supported by an appropriate assessment. Where the deviation does affect interpretation, the limitation should be carried into the final scientific conclusion rather than hidden in an operational record.

6. Interim Results Are Different From Final Results

A PASS may generate interim analyses, progress information or feasibility findings before the final study report. These outputs can be useful, but they should remain distinguishable from the final evidence set.

For imposed non-interventional PASS, EMA states that interim results and feasibility studies do not fall under the Article 107n–q procedure governing the final study report. Where such information is requested, the applicable submission route depends on the circumstances. citeturn1view1

The distinction does not mean that interim findings are unimportant. It means that the status of the evidence must be accurately represented. An interim analysis should not be presented as though it were the completed answer to the primary study question.

7. Important Safety Information Must Not Wait for Study Closure

The distinction between interim and final reporting should never be interpreted as permission to delay action on important safety information.

GVP Module VIII requires the MAH to monitor information generated during the study and consider its implications for the risk-benefit balance. New information that may affect the risk-benefit balance is to be communicated as an emerging safety issue through the applicable regulatory process. The module also links study findings to PSUR and RMP processes. citeturn0search22

This produces an important operational distinction:

the final report answers the study question; ongoing pharmacovigilance determines whether information generated before final reporting requires action sooner.

The study therefore remains part of the pharmacovigilance system throughout its conduct rather than becoming relevant only when the final report is approved.

8. Individual Safety Information Collected During the Study

Where a PASS involves primary data collection and identifies individual suspected adverse reactions, those cases remain subject to the applicable pharmacovigilance requirements.

GVP Module VIII explicitly links reporting of suspected adverse reactions to GVP Module VI and states that adverse events or adverse reactions collected in studies with primary data collection should be recorded and summarised in interim safety analyses and the final study report. citeturn0search22

The practical consequence is that study data collection and case-processing activities need a defined interface. A PASS should not become an isolated data repository in which potentially reportable safety information is separated from the organisation's normal PV processes.

9. The Final Result Must Be Considered in the Totality of Evidence

The PASS conclusion is an important input to the safety profile, but it is not necessarily the final pharmacovigilance conclusion.

The organisation should consider the result alongside other relevant evidence, which may include:

• spontaneous reports;
• literature;
• clinical studies;
• other observational studies;
• signal-management outputs;
• previous aggregate assessments;
• regulatory actions;
• and risk-management measures.

A PASS can strengthen, weaken or refine an existing safety concern. It can also introduce a new concern. The appropriate interpretation depends on how the new evidence fits with the existing evidence base.

This is why a completed study should trigger an explicit pharmacovigilance impact assessment rather than simply being filed as a completed project.

10. From Safety Findings to Benefit-Risk and Risk Management

The next question is whether the evidence changes the safety profile or benefit-risk balance and, where relevant, the RMP.

A safety finding does not automatically mean that the overall benefit-risk balance has become unfavourable. Its significance depends on factors such as clinical seriousness, magnitude and uncertainty of the risk, affected population, treatment benefits, alternative options and existing risk controls.

Where the PASS addresses an RMP safety concern, missing information or risk-minimisation objective, the organisation should assess the result against that RMP component. The consequence may be no change, refinement of the safety characterisation, additional pharmacovigilance, modification of risk minimisation, an RMP update or another regulatory action.

The important control is the assessment itself. A conclusion that the RMP does not require change should still be supported by evidence showing that the result was considered.

Key Takeaways

PASS results are the point at which a defined safety question is converted into evidence and then into a pharmacovigilance decision.

A defensible process distinguishes the original question, the evidence actually generated, the uncertainty that remains and the action that follows. It also distinguishes interim information from final results and scientific completion from regulatory closure.

For imposed non-interventional PASS, the final report enters a formal EU regulatory process. For all PASS, however, important findings remain part of ongoing pharmacovigilance and must be assessed in the context of the wider safety profile.

References

1. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module VIII — Post-authorisation safety studies, Revision 3.
2. European Medicines Agency. Post-authorisation safety studies (PASS), including current procedural guidance and questions and answers.
3. European Medicines Agency. Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies.
4. European Medicines Agency. GVP Module VIII Addendum I — Requirements and recommendations for submission of information on non-interventional PASS.
5. Directive 2001/83/EC, as amended, Articles 107m–107q.
6. Commission Implementing Regulation (EU) No 520/2012, as amended.
7. European Medicines Agency. GVP Module VI — Management and reporting of adverse reactions.

Regulatory Note

This article distinguishes legal requirements, GVP guidance and recommended operational practice. Current legislation and EMA procedural guidance should be verified before applying specific submission requirements or timelines. Practical examples and inspection considerations are illustrative unless an authoritative source is specifically identified.

11. From Scientific Interpretation to Regulatory Reporting

Once the findings have been interpreted, the next question is how they enter the applicable regulatory framework. This follows from the status of the PASS itself. The scientific result is the same kind of evidence regardless of whether the study was imposed or voluntary, but the regulatory consequences of producing and submitting that evidence are not necessarily the same.

For an imposed non-interventional PASS, the final study report enters the specific EU procedure established for imposed PASS. EMA states that the final study report is assessed by PRAC and that the assessment can lead to recommendations concerning the marketing authorisation. The current EMA procedural guidance also distinguishes the formal requirements for imposed PASS from the recommendations applicable to voluntary PASS. citeturn0search0turn0search10

This distinction should be established before the organisation determines how the result will be submitted and followed up. Otherwise, the scientific conclusion and the regulatory pathway can become confused with one another.

12. The Imposed PASS Assessment Process

For an imposed non-interventional PASS, the final report is not simply the document that closes a study project. It becomes part of a defined regulatory process.

The current EMA procedure provides for submission and validation of the final study report followed by regulatory assessment. For an imposed non-interventional PASS, the assessment is performed by PRAC under the applicable Article 107q procedure. The procedure can involve centrally authorised products, nationally authorised products, or a combination of both, depending on the products and the applicable legal framework. citeturn0search0turn0search23

This creates two distinct activities. The first is producing a scientifically complete report that accurately represents the study. The second is managing the regulatory process that follows submission. A controlled PASS system therefore needs a traceable connection between the submitted report, validation, regulatory correspondence, assessment outcome and implementation.

The distinction becomes particularly useful when responsibility is divided between study teams, pharmacovigilance, regulatory affairs and external providers. Each function may own part of the process, but the product-level regulatory history must remain coherent.

13. The MAH Conclusion and the Regulatory Conclusion

The MAH's scientific conclusion and the regulator's conclusion are related but are not the same record.

The final study report should state what the study found and how the MAH interprets those findings. The subsequent regulatory assessment may agree with that interpretation, identify additional uncertainty, request clarification or lead to regulatory action. These stages should therefore remain distinguishable in the records.

A useful evidence chain is:

What the study found
        ↓
What the MAH concluded
        ↓
What the regulator concluded
        ↓
What action followed

Maintaining this distinction is more than document-management discipline. It preserves the scientific and regulatory history of the product and prevents a later reviewer from confusing an MAH assessment with a regulatory decision.

14. When Results Affect the Marketing Authorisation

Once the scientific significance of the results has been established, the organisation must determine whether they have implications for the marketing authorisation.

EMA states that the MAH should evaluate the results of an imposed non-interventional PASS for their impact on the marketing authorisation. Where the MAH considers that a variation is necessary, the appropriate regulatory procedure should be followed. Independently, the PRAC assessment of the final study report may lead to regulatory recommendations. citeturn0search0turn0search23

The important conceptual point is that the study result does not itself amend the marketing authorisation. The result supplies evidence; the applicable regulatory mechanism produces the legal or regulatory change.

Study result
     ↓
Scientific impact assessment
     ↓
Marketing-authorisation assessment
     ↓
Applicable regulatory procedure
     ↓
Regulatory implementation

This distinction becomes important when a study identifies evidence relevant to product information, risk minimisation or another component of the authorisation. The evidence must be translated through the appropriate regulatory route rather than treated as self-executing.

15. Product Information as a Consequence of the Results

A PASS may generate evidence relevant to warnings, precautions, adverse reactions, contraindications or other elements of product information. Whether a change is required depends on the evidence and the applicable regulatory framework.

For an imposed non-interventional PASS, current EMA procedural guidance states that proposed product-information changes resulting from data contained in the final study report can be considered within the Article 107q procedure. Where a proposed change is not based on data contained in that report, it is not handled through that route and an appropriate variation must be submitted. citeturn0search23

This creates a direct traceability requirement. The organisation should be able to identify the evidence supporting a proposed change and demonstrate why the selected regulatory mechanism applies. The final product-information wording is therefore not simply an editorial consequence of the study report; it is the outcome of a documented scientific and regulatory assessment.

16. RMP Reassessment Follows From the Safety Question

The same reasoning applies to the RMP. Where the PASS addresses a safety concern, missing information or risk-minimisation objective represented in the RMP, the result should be assessed against the relevant RMP component.

The assessment may conclude that no change is necessary. Alternatively, the evidence may support a change to the safety specification, further pharmacovigilance activity, risk characterisation, risk minimisation or another element of the risk-management system.

The important control is the assessment itself. An RMP should not be assumed to remain unchanged merely because the study was managed by a study function rather than by the RMP team. Conversely, a change should not be made merely because a PASS produced a new result. The result must first be interpreted in the context of the wider safety profile.

For imposed PASS, EMA's current procedural guidance also specifies circumstances in which an RMP update resulting directly from the final study report may accompany the report, while other situations require the appropriate separate regulatory procedure. citeturn0search23

17. Risk-Minimisation Effectiveness Requires a Different Interpretation

A PASS evaluating risk-minimisation effectiveness asks a different question from a study designed primarily to estimate or characterise a risk. The central issue is whether the measure achieved its predefined objective.

That requires the organisation to distinguish implementation from effectiveness. A communication may have been distributed without reaching the intended population. The population may have received the communication without demonstrating the expected knowledge or behaviour. Behaviour may have changed without demonstrating the intended clinical outcome.

The interpretation should therefore follow the effectiveness objectives established in the protocol. If the study identifies inadequate effectiveness, the result becomes evidence for a subsequent risk-management decision rather than the decision itself.

This distinction is important because a PASS report should explain what the study demonstrated, while the pharmacovigilance system must determine what should happen as a consequence.

18. Results Enter the Wider Signal-Management Process

A PASS does not exist outside the cumulative safety evaluation. Its results may strengthen an existing concern, reduce uncertainty, provide evidence against a suspected association or identify a concern that was not previously recognised.

The appropriate response is therefore to place the result alongside the other evidence relevant to the safety issue. Where the PASS was initiated in response to a particular signal, the organisation should explicitly consider whether the study has resolved the uncertainty that led to the study. Where it has not, the remaining uncertainty should be identified rather than hidden by a formal declaration of study completion.

Equally, evidence against an association should not automatically close every related safety activity. The result must be considered with spontaneous reports, literature, clinical data, other studies and the characteristics and limitations of each evidence source.

The purpose of the post-study assessment is therefore integration, not selection of the evidence source that produces the most convenient conclusion.

19. Results Become Part of Subsequent Aggregate Evaluation

The lifecycle continues after the final report and any immediate regulatory procedure. Where relevant, PASS findings become part of subsequent aggregate safety evaluation, including PSURs.

This creates an important temporal relationship. A later PSUR should be able to explain, where relevant, what the PASS established, what action followed and whether later evidence changed the interpretation. The PASS therefore becomes part of the cumulative safety history rather than a document that is closed and forgotten once its immediate procedure has ended.

The interface needs to work in both directions. A PSUR may identify a need for further study, while the completed PASS may subsequently provide evidence that changes a later aggregate assessment. Maintaining that continuity is a pharmacovigilance-system responsibility even when different functions or vendors manage the individual activities.

20. Public Transparency Is Part of the Results Lifecycle

Regulatory follow-up also has a transparency dimension. EMA publishes PASS protocols, abstracts and final study reports through the HMA-EMA Catalogue of real-world data studies, which replaced the EU PAS Register. The current EMA PASS page states that MAHs should register their PASS in the catalogue to enable publication. citeturn0search0

For imposed non-interventional PASS, the catalogue therefore forms part of the visible lifecycle of the study. The public record should remain consistent with the study's actual status and with the documents that have been formally submitted or finalised.

The distinction between legal requirements and recommended practice also matters here. EMA and the catalogue guidance specify mandatory requirements for PASS conducted pursuant to a regulatory obligation, while similar format and content standards are recommended for voluntary PASS to support consistent transparency, scientific quality and reproducibility. citeturn0search1

21. Regulatory Follow-Up After Assessment

Once the regulatory assessment has produced an outcome, the organisation has to translate that outcome into controlled product-level action where action is required.

The implementation pathway depends on the regulatory outcome, the products involved and their authorisation status. Current EMA guidance distinguishes implementation for centrally authorised and nationally authorised products and notes that products not directly involved in the procedure may nevertheless be affected when the adopted changes apply to their marketing authorisations. citeturn0search0

A controlled implementation process therefore needs to identify the regulatory conclusion, affected products, required changes, applicable procedures, responsible functions, deadlines and evidence that implementation has actually occurred.

The final step is verification. A task marked complete in a tracker is not equivalent to demonstrating that the required regulatory or product change was implemented correctly.

22. When No Regulatory Change Is Required

Not every PASS result leads to a change in the marketing authorisation. A study may confirm the existing safety profile, reduce an important uncertainty or demonstrate that an existing risk-minimisation measure remains appropriate.

In such circumstances, no regulatory change is itself an assessed outcome. The organisation should be able to explain why the evidence does not require a change to the safety profile, RMP, product information, risk minimisation or other relevant controls.

This is an important distinction for inspection readiness. The absence of an action should not be indistinguishable from the absence of an assessment. A documented conclusion of no action demonstrates that the evidence was considered and that the organisation deliberately reached that outcome.

23. When the Evidence Contradicts Earlier Knowledge

A PASS may produce findings that differ from spontaneous reports, clinical trials, literature, other studies or previous aggregate assessments. Such disagreement does not automatically mean that one source is wrong.

The evidence should first be compared on its underlying characteristics: population, exposure, outcome definition, follow-up, ascertainment, confounding, missingness, data quality and study design. A difference may reflect a genuine change in risk, a difference in the population studied, or a methodological limitation.

The subsequent pharmacovigilance assessment should therefore integrate the evidence rather than selecting one source as the preferred answer. Where the new evidence changes the overall interpretation, that change should be reflected in the appropriate downstream processes.

24. Practical Example: A PASS Confirms an Existing Risk

Consider a PASS designed to characterise an already recognised risk. The study produces results consistent with the existing safety profile and does not materially alter the understanding of the risk.

The study has nevertheless reduced uncertainty and may strengthen the evidence supporting the existing conclusion. The organisation should document that interpretation and consider whether the result affects the RMP, signal management, product information or subsequent PSURs.

The outcome is therefore not necessarily a new regulatory measure. It may instead be a better-supported existing safety conclusion.

25. Practical Example: A PASS Challenges Risk-Minimisation Effectiveness

Consider a PASS evaluating whether an additional risk-minimisation measure achieves a predefined behavioural objective. The study finds that the intended population has substantially lower awareness than expected.

The first question is whether the finding meets the prespecified criteria for effectiveness established in the study. If it does, the result becomes evidence for reassessing the risk-minimisation strategy.

The study has answered an effectiveness question; the subsequent pharmacovigilance and regulatory assessment determines what should change. Keeping those two decisions separate prevents the study report from becoming a substitute for the risk-management decision that follows it.

26. Practical Example: A Final Result Raises a New Safety Concern

Suppose a PASS identifies an association that was not anticipated in the original safety specification. Formal completion of the study does not remove the need to assess that finding.

The organisation should initiate the appropriate pharmacovigilance assessment and consider the evidence alongside other available information. Depending on the strength and nature of the evidence, this may lead to signal-management activity, reassessment of the RMP or product information, further evidence generation or another regulatory action.

The important principle is that the PASS provides evidence; the pharmacovigilance system determines its significance and controls the resulting action.

Key Takeaways

The final study report is the bridge between study evidence and the wider pharmacovigilance and regulatory system. For imposed non-interventional PASS, the report enters a defined regulatory assessment process. For voluntary PASS, the formal pathway differs, although EMA recommends comparable reporting standards and the MAH remains responsible for assessing significant findings.

The downstream assessment should answer a connected set of questions: what did the study establish, how certain is that conclusion, does it change the safety profile or benefit-risk assessment, and what does that mean for the RMP, risk minimisation, product information, signal management and subsequent aggregate evaluation?

A conclusion of no regulatory action is therefore still a conclusion requiring evidence and reasoning. Conversely, where action is required, regulatory follow-up is not complete until the affected products and processes have been identified, the appropriate mechanism has been used and implementation has been verified.

27. From Regulatory Outcome to Follow-Up

Once the scientific and regulatory assessments are complete, the organisation must determine what happens next. This is the point at which a PASS becomes part of the continuing pharmacovigilance system rather than remaining a completed study project.

The appropriate follow-up depends on what the evidence established, what uncertainty remains, and, where applicable, what the regulatory assessment requires. Possible outcomes include continued monitoring, additional analysis, further evidence generation, signal-management activity, an RMP change, additional risk minimisation, product-information action, a regulatory procedure or a documented decision that no further action is required.

The choice should therefore follow from the evidence and the decision made about its significance. It should not be selected simply because it is the next available project-management step.

28. When the Original Question Remains Unresolved

A study can be completed without completely resolving the safety question that led to it. This is not necessarily a failure of the study. Some questions remain uncertain because of limited precision, residual confounding, insufficient exposure, incomplete outcome ascertainment, an unrepresentative population or an unexpected finding requiring confirmation.

The correct response is to identify the remaining uncertainty explicitly and determine what evidence could address it. If another study is needed, its design should respond to the limitation that prevented the first study from answering the question rather than simply reproducing the same approach.

This distinction matters because study completion and scientific resolution are different concepts. A PASS may reach its formal endpoint while still generating a need for further pharmacovigilance activity.

29. Regulatory Commitments and Study Completion

When a PASS is linked to a formal regulatory obligation, several milestones that appear to belong to one activity may have different regulatory meanings. Study completion, final-report submission, regulatory assessment, resolution of authority questions, implementation of the outcome and closure of the commitment should therefore be tracked separately.

For an imposed non-interventional PASS, the final study report enters a defined regulatory procedure and the resulting assessment can create further obligations. citeturn0search0

The internal record should consequently not mark a regulatory commitment as closed merely because the study database has been locked or the final report has been approved. Closure requires evidence that the applicable downstream obligations have also been addressed.

30. Delays and Changes to the Planned Timeline

A delay to a PASS is more than a project-management event when the study has a regulatory obligation. The organisation should determine whether the delay affects a regulatory milestone, a marketing-authorisation condition, the timing of safety information or the ability to answer an important pharmacovigilance question.

Where the applicable procedure requires regulatory interaction, the organisation should follow that procedure rather than relying solely on an internally revised project plan. Current EMA procedural guidance provides specific mechanisms for changes affecting imposed PASS milestones and, where relevant, corresponding marketing-authorisation conditions. citeturn0search0

The broader principle is that a study timeline can itself form part of the regulatory control system. Timeline governance should therefore connect project management with pharmacovigilance and regulatory oversight.

31. When No Additional Action Is Required

A mature pharmacovigilance process must be capable of reaching a conclusion of no further action when the evidence supports it.

For example, the study may adequately address the original question, confirm the existing risk characterisation and provide no evidence that additional intervention is required. In that situation, the absence of a new measure is an assessed outcome rather than an absence of decision-making.

The record should explain the reasoning sufficiently for a later reviewer to understand why further action was not considered necessary. This is particularly important when the study was undertaken because of a previously identified uncertainty: the organisation should be able to demonstrate that the uncertainty was considered and resolved or reduced sufficiently to support the conclusion.

32. QPPV and Governance Review

For a significant PASS, the QPPV or appropriate pharmacovigilance governance forum should have sufficient visibility of the study's conclusions and consequences. This does not mean that the QPPV must perform every technical study activity. It means that significant safety evidence should enter the appropriate pharmacovigilance and regulatory decision pathways.

The review should establish, as appropriate, what the study found, how certain the findings are, what limitations affect interpretation, whether the safety profile has changed, whether an existing signal is affected, whether the RMP requires reassessment, whether risk minimisation is affected, whether subsequent PSURs need to incorporate the evidence, whether product information requires assessment, whether regulatory commitments remain open and whether further evidence is required.

These questions turn study completion into a pharmacovigilance decision rather than an administrative endpoint.

33. Evidence and Traceability for Inspection

The most useful inspection model is an evidence chain connecting the original question to the eventual action:

Safety question
      ↓
Protocol
      ↓
Study conduct
      ↓
Data and analysis
      ↓
Results
      ↓
Scientific interpretation
      ↓
Final report
      ↓
PV impact assessment
      ↓
Regulatory assessment, where applicable
      ↓
Action or documented no-action
      ↓
Implementation
      ↓
Follow-up / closure

The organisation should be able to demonstrate these relationships without requiring an inspector to reconstruct the history from unrelated records and individual recollection.

This does not require one document containing every step. It requires controlled records that can be connected and whose responsibilities, dates, decisions and evidence are sufficiently clear.

34. Inspection Scenario: The Final Report Is the Only Evidence

An inspector asks what changed in the pharmacovigilance system as a result of the PASS. The organisation can produce the final report but cannot demonstrate an assessment of its implications for the RMP, signal management, PSUR, product information or regulatory commitments.

The weakness is not necessarily that a change was required. The weakness is that the organisation cannot demonstrate that the implications were evaluated. The appropriate inspection response would therefore focus on the missing decision record and evidence of governance rather than assuming that a regulatory change should have occurred.

35. Inspection Scenario: An Interim Finding Was Not Escalated

A study team identifies a potentially important finding during an interim analysis but waits for the final report before informing pharmacovigilance.

The underlying weakness is treating study completion as a prerequisite for safety assessment. Where emerging information may materially affect patient safety or the regulatory position, the study governance model should provide a route for timely escalation and assessment.

The relevant inspection question is not simply whether the interim result was eventually reported. It is whether the organisation had an effective mechanism for recognising and escalating important emerging evidence.

36. Inspection Scenario: The Regulatory Submission Cannot Be Reconstructed

The organisation knows that the final study report was submitted but cannot produce the controlled submitted version, approval evidence or relevant regulatory correspondence.

This creates a records and regulatory-control weakness because the organisation cannot reconstruct what was submitted or how the authority interaction was managed. A controlled submission record should therefore be retained alongside the final report and subsequent regulatory correspondence.

37. Inspection Scenario: The RMP Conclusion Was Assumed

The final report states that the study has no implications for the RMP, but there is no evidence that the RMP was actually assessed.

The conclusion may ultimately be correct. The weakness is the absence of evidence supporting the conclusion. An effective process should make the assessment visible, even where the outcome is that no RMP change is required.

38. Inspection Scenario: The Vendor's Conclusion Was Accepted Without Challenge

A vendor prepares the final report and concludes that the study does not alter the safety profile. Internal records contain no evidence of meaningful medical or pharmacovigilance review.

Outsourcing study execution does not transfer the MAH's responsibility for assessing the significance of the results. The organisation should retain sufficient expertise and evidence of review to demonstrate appropriate oversight.

The issue is therefore not that a vendor participated. It is whether the MAH retained effective control over the scientific interpretation and its consequences.

39. Inspection Scenario: The Study Was Closed Before the Regulatory Activity

The study database was locked and the final report approved, but an outstanding regulatory commitment, authority question or implementation activity remained open.

The organisation has confused scientific completion with regulatory closure. A sound closure process should identify downstream obligations and confirm their completion before the activity is considered fully closed.

40. A Mature Results-to-Action Model

The preceding sections can be brought together into one decision pathway:

Study result
     ↓
Scientific interpretation
     ↓
Uncertainty assessment
     ↓
Safety impact assessment
     ↓
RMP / signal / PSUR / risk-minimisation interfaces
     ↓
Regulatory assessment, where applicable
     ↓
Action or documented no-action
     ↓
Implementation
     ↓
Effectiveness / continued monitoring
     ↓
Closure

This model explains why governance continues after the final report. Evidence must first be translated into a justified decision, and the decision must then be translated into controlled action where necessary. Where no action is required, that conclusion must still be supported by the evidence and documented reasoning.

41. Final Review Questions

Before a significant PASS is considered complete, the organisation should be able to answer, from controlled evidence:

1. What safety question was the study intended to answer?
2. Did the study answer that question, and with what degree of certainty?
3. What limitations affect interpretation?
4. What did the results add to the existing safety profile?
5. Were unexpected findings assessed?
6. Was the RMP impact assessed?
7. Was signal-management impact assessed?
8. Was risk-minimisation effectiveness assessed where relevant?
9. Was product-information impact assessed?
10. Was the result incorporated into subsequent aggregate assessment where applicable?
11. What regulatory procedure applied?
12. What regulatory outcome resulted?
13. Which products and commitments are affected?
14. Have required actions been implemented and verified?
15. Is further evidence or monitoring required?
16. Can the complete evidence-to-action chain be reconstructed?

These questions are not a substitute for the applicable legal or procedural requirements. They provide a governance test of whether the study has been integrated into the pharmacovigilance system rather than treated as an isolated research project.

Key Takeaways

The purpose of PASS results reporting is not simply to document what the study found. It is to convert evidence into an appropriately justified pharmacovigilance and, where applicable, regulatory response.

A strong process preserves continuity from the original safety question through study conduct, interpretation, reporting, regulatory assessment, implementation and follow-up. It distinguishes scientific completion from regulatory closure and distinguishes a decision of no action from an absence of decision-making.

The strongest inspection record is therefore not the final study report alone. It is the connected evidence showing what was learned, how the organisation interpreted it, what changed as a result, and why the resulting action or no-action conclusion was appropriate.

References

1. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module VIII — Post-authorisation safety studies.
2. European Medicines Agency. Post-authorisation safety studies (PASS), including current procedural advice and questions and answers.
3. European Medicines Agency. Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies.
4. European Medicines Agency. HMA-EMA Catalogue of real-world data studies.
5. European Medicines Agency. GVP Module V — Risk management systems.
6. European Medicines Agency. GVP Module VII — Periodic safety update report.
7. Commission Implementing Regulation (EU) No 520/2012, as amended.
8. Directive 2001/83/EC, as amended.

Regulatory Note

This article explains the EU framework for PASS results, reporting and regulatory follow-up. It does not replace current legislation, GVP guidance, EMA procedural requirements, regulatory commitments or an organisation's approved procedures.

Regulatory requirements and procedures may change. Current EMA and EU requirements should be verified when applying this guidance to an actual PASS.

Inspection scenarios and practical examples are illustrative unless an authoritative source is specifically identified.